PureTech Health (CHIX:PRTCL) 6-Month Price Index: 0.97 (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:PRTCL PureTech Health PLC CHIX:PRTCL
62 GF Score
Price £1.20
GF Value £5.45
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is PureTech Health 6-Month Price Index?

PureTech Health CHIX:PRTCL +2.56% 62 6-Month Price Index is 0.97 as of Aug. 25, 2026. GuruFocus rates CHIX:PRTCL with a GF Score™ of 62/100 and a GF Value™ of £5.45 (Possible Value Trap). The stock has 3 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-25), PureTech Health's 6-Month Price Index is 0.97.

PureTech Health  (CHIX:PRTCl) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

PureTech Health 6-Month Price Index Related Terms

CHIX:PRTCL vs VRTX, REGN, RVMD: 6-Month Price Index Comparison

For the Biotechnology subindustry, PureTech Health's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CHIX:PRTCL
62GF Score
PureTech Health PLC CHIX:PRTCL
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PureTech Health  (CHIX:PRTCl) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.97 mean?
PureTech Health (CHIX:PRTCL) has a 6-Month Price Index of 0.97 as of Aug. 25, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on PureTech Health and its competitors.
Is PureTech Health's 6-Month Price Index too high?
PureTech Health's current 6-Month Price Index is 0.97. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's 6-Month Price Index compare to VRTX and REGN?
PureTech Health's 6-Month Price Index of 0.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on PureTech Health and its competitors. PureTech Health's current 6-Month Price Index is 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (CHIX:PRTCL) is currently considered Possible Value Trap. The stock's GF Value™ is £5.45, compared to a current price of £1.20 — trading 77.9% below its estimated fair value. The current 6-Month Price Index is 0.97. PureTech Health's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For PureTech Health (CHIX:PRTCL), the current 6-Month Price Index is 0.97 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PureTech Health (CHIX:PRTCL) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of £1.20 is trading 77.9% below its estimated GF Value™ of £5.45. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for CHIX:PRTCL:

  • 6-Month Price Index: 0.97
  • GF Value™: £5.45 vs. price of £1.20 (77.9% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the CHIX:PRTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score

Get the complete analysis for CHIX:PRTCL

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.20
Price
£5.45
GF Value